



Toxicological Profile for 1,1,1-Trichloroethane

March 2024



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute-, intermediate-, and chronic-duration exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher M. Reh, Ph.D.

Associate Director

Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
March 2024	Final toxicological profile released
January 2023	Draft for public comment toxicological profile released
July 2006	Final toxicological profile released
August 1995	Final toxicological profile released
December 1990	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Carolyn Harper, Ph.D. (Lead)
Brittany Szafran, DVM, Ph.D.
Jennifer Przybyla, Ph.D.
Kambria Haire, M.P.H., Ph.D.
Melanie Buser, M.P.H.
ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

Ryan Klein, Ph.D.
Kerry Diskin, Ph.D.
Hannah Derrick, B.S.
Meghan Lynch, DSc.
Abt Associates, Rockville, MD

Claire Heit, Ph.D.
Julie M. Klotzbach, Ph.D.
Savannah Sierco, M.S.
Mario Citra, Ph.D.
SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences; NCEH, Division of Environmental Health Science and Practice; EPA, Office of Research and Development; EPA, Office of Water.

PEER REVIEWERS

1. Lawrence H. Lash, Ph.D., Editor, Toxicology and Applied Pharmacology, Editor, Toxicology Reports, Professor, Department of Pharmacology, Wayne State University School of Medicine, 540 East Canfield Avenue, Detroit, Michigan
2. G.A. Shakeel Ansari, Ph.D., Professor Emeritus, Department of Pathology, 2.318 MMNP, University of Texas Medical Branch, Galveston, Texas
3. Jeffrey Fisher, Ph.D., Senior Science Fellow for the Computational Biology, Division of ScitoVation, 100 Capitola Drive, Suite 106, Durham, North Carolina

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	iv
CONTRIBUTORS & REVIEWERS	v
CONTENTS	vi
LIST OF FIGURES	viii
LIST OF TABLES	ix
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS	2
1.3 MINIMAL RISK LEVELS (MRLS)	6
CHAPTER 2. HEALTH EFFECTS	10
2.1 INTRODUCTION	10
2.2 DEATH	70
2.3 BODY WEIGHT	72
2.4 RESPIRATORY	74
2.5 CARDIOVASCULAR	75
2.6 GASTROINTESTINAL	76
2.7 HEMATOLOGICAL	77
2.8 MUSCULOSKELETAL	78
2.9 HEPATIC	79
2.10 RENAL	82
2.11 DERMAL	83
2.12 OCULAR	85
2.13 ENDOCRINE	86
2.14 IMMUNOLOGICAL	86
2.15 NEUROLOGICAL	87
2.16 REPRODUCTIVE	93
2.17 DEVELOPMENTAL	95
2.18 OTHER NONCANCER	97
2.19 CANCER	97
2.20 GENOTOXICITY	102
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	106
3.1 TOXICOKINETICS	106
3.1.1 Absorption	106
3.1.2 Distribution	110
3.1.3 Metabolism	112
3.1.4 Excretion	115
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	118
3.1.6 Animal-to-Human Extrapolations	126
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	126
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	128

3.3.1	Biomarkers of Exposure.....	129
3.3.2	Biomarkers of Effect.....	131
3.4	INTERACTIONS WITH OTHER CHEMICALS.....	132
CHAPTER 4.	CHEMICAL AND PHYSICAL INFORMATION.....	136
4.1	CHEMICAL IDENTITY.....	136
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	136
CHAPTER 5.	POTENTIAL FOR HUMAN EXPOSURE.....	138
5.1	OVERVIEW.....	138
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL.....	140
5.2.1	Production.....	140
5.2.2	Import/Export.....	142
5.2.3	Use.....	142
5.2.4	Disposal.....	143
5.3	RELEASES TO THE ENVIRONMENT.....	143
5.3.1	Air.....	144
5.3.2	Water.....	147
5.3.3	Soil.....	147
5.4	ENVIRONMENTAL FATE.....	148
5.4.1	Transport and Partitioning.....	148
5.4.2	Transformation and Degradation.....	149
5.5	LEVELS IN THE ENVIRONMENT.....	152
5.5.1	Air.....	154
5.5.2	Water.....	155
5.5.3	Sediment and Soil.....	157
5.5.4	Other Media.....	157
5.6	GENERAL POPULATION EXPOSURE.....	158
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES.....	160
CHAPTER 6.	ADEQUACY OF THE DATABASE.....	162
6.1	EXISTING INFORMATION ON HEALTH EFFECTS.....	162
6.2	IDENTIFICATION OF DATA NEEDS.....	164
6.3	ONGOING STUDIES.....	173
CHAPTER 7.	REGULATIONS AND GUIDELINES.....	174
CHAPTER 8.	REFERENCES.....	177
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS.....	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR 1,1,1-TRICHLOROETHANE.....	B-1
APPENDIX C.	FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR 1,1,1-TRICHLOROETHANE.....	C-1
APPENDIX D.	USER'S GUIDE.....	D-1
APPENDIX E.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	E-1
APPENDIX F.	GLOSSARY.....	F-1
APPENDIX G.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	G-1

LIST OF FIGURES

1-1. Health Effects Found in Humans Following Inhalation Exposure to 1,1,1-Trichloroethane	3
1-2. Health Effects Found in Animals Following Inhalation Exposure to 1,1,1-Trichloroethane	4
1-3. Health Effects Found in Animals Following Oral Exposure to 1,1,1-Trichloroethane	5
1-4. Summary of Sensitive Targets of 1,1,1-Trichloroethane – Inhalation.....	7
1-5. Summary of Sensitive Targets of 1,1,1-Trichloroethane – Oral.....	8
2-1. Overview of the Number of Studies Examining 1,1,1-Trichloroethane Health Effects	13
2-2. Levels of Significant Exposure to 1,1,1-Trichloroethane – Inhalation.....	41
2-3. Levels of Significant Exposure to 1,1,1-Trichloroethane – Oral.....	62
3-1. Metabolic Scheme for 1,1,1-Trichloroethane	113
3-2. Scatter Diagram Relating TWA of Environmental Concentration and Urinary Concentration of 1,1,1-Trichloroethane in Exposed Workers	131
5-1. Number of NPL Sites with 1,1,1-Trichloroethane Contamination	138
6-1. Summary of Existing Health Effects Studies on 1,1,1-Trichloroethane by Route and Endpoint.....	163

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for 1,1,1-Trichloroethane	9
2-1. Occupational Inhalation Exposures to 1,1,1-Trichloroethane and Health Outcome Associations.....	14
2-2. Levels of Significant Exposure to 1,1,1-Trichloroethane – Inhalation.....	18
2-3. Levels of Significant Exposure to 1,1,1-Trichloroethane – Oral.....	56
2-4. Levels of Significant Exposure to 1,1,1-Trichloroethane – Dermal.....	68
2-5. Summary of Epidemiological Studies Evaluating Possible Associations Between 1,1,1-Trichloroethane Exposure and Risk of Selected Cancer Types	98
2-6. Genotoxicity of 1,1,1-Trichloroethane <i>In Vivo</i>	102
2-7. Genotoxicity of 1,1,1-Trichloroethane <i>In Vitro</i>	103
3-1. Parameters Used in the Physiologically Based Pharmacokinetic Model for 1,1,1-Trichloroethane Developed by Reitz et al. (1988).....	120
4-1. Chemical Identity of 1,1,1-Trichloroethane	136
4-2. Physical and Chemical Properties of 1,1,1-Trichloroethane	137
5-1. Facilities that Produce, Process, or Use 1,1,1-Trichloroethane	141
5-2. Releases to the Environment from Facilities that Produce, Process, or Use 1,1,1-Trichloroethane.....	144
5-3. National Emission Inventory (NEI) Total National Emissions for 1,1,1-Trichloroethane Estimated by Sector 2017	145
5-4. Lowest Limit of Detection for 1,1,1-Trichloroethane Based on Standards.....	153
5-5. Summary of Environmental Levels of 1,1,1-Trichloroethane.....	153
5-6. 1,1,1-Trichloroethane Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	153
5-7. Percentile Distribution of Mean 1,1,1-Trichloroethane Concentrations (ppbv) Measured in Ambient Air at Locations Across the United States	154
5-8. Summary of Concentrations of 1,1,1-Trichloroethane ($\mu\text{g/L}$) Measured in Surface and Groundwater Across the United States.....	155
5-9. RME Daily Inhalation Dose ($\mu\text{g}/\text{m}^3$) and Administered Dermal Dose ($\mu\text{g}/\text{kg}/\text{day}$) for the Target Person.....	158
7-1. Regulations and Guidelines Applicable to 1,1,1-Trichloroethane.....	174